MIROBIO
MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control.
MIROBIO
Social Links:
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.mirobio.com
Total Employee:
1+
Status:
Active
Contact:
01865 618817
Email Addresses:
[email protected]
Total Funding:
107 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Refeyn
Refeyn is specialising in label-free single molecule imaging and mass measurement.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
OrbiMed
OrbiMed investment in Series B - MiroBio
SR One
SR One investment in Series B - MiroBio
Medicxi
Medicxi investment in Series B - MiroBio
Samsara BioCapital
Samsara BioCapital investment in Series B - MiroBio
Oxford Science Enterprises
Oxford Science Enterprises investment in Series B - MiroBio
Advent Life Sciences
Advent Life Sciences investment in Series B - MiroBio
Monograph Capital
Monograph Capital investment in Series B - MiroBio
SR One
SR One investment in Series A - MiroBio
Advent Life Sciences
Advent Life Sciences investment in Series A - MiroBio
Samsara BioCapital
Samsara BioCapital investment in Series A - MiroBio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-21 | Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies |
Official Site Inspections
http://www.mirobio.com
- Host name: 165.160.15.20
- IP address: 165.160.15.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MiroBio"
Gilead Sciences to Acquire MiroBio
Aug 4, 2022 · MiroBio is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune …See details»
Oxford Science Enterprises portfolio company MiroBio to be …
Aug 3, 2022 · MiroBio is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune …See details»
Gilead Sciences Completes Acquisition of MiroBio
Sep 20, 2022 · MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical …See details»
Oxford spinout MiroBio acquired by Gilead Sciences for $405m
Aug 4, 2022 · MiroBio, an Oxford biotech spinout focused on therapeutics for inflammatory diseases, is set to be acquired by global biopharmaceutical company Gilead Sciences …See details»
MiroBio - Oxford Science Enterprises
MiroBio is a clinical-stage biotech company harnessing the natural 'brakes' of the immune system to control the symptoms of auto-immune diseases. The company was acquired by Gilead Sciences in 2022.See details»
MiroBio - Crunchbase Company Profile & Funding
MiroBio is Harnessing the natural control mechanisms of the immune system. View contacts for MiroBio to access new leads and connect with decision-makers. MiroBio's platform is based on ground-breaking research by their scientific …See details»
Gilead Sciences, Inc. - Gilead Sciences to Acquire MiroBio
Aug 4, 2022 · MiroBio is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune …See details»
Oxford Science Enterprises portfolio company MiroBio to be …
Aug 4, 2022 · MiroBio is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune …See details»
MiroBio Ltd - LinkedIn
Our mission at MiroBio is to deliver transformational immunotherapies for people suffering from autoimmune disease. Immune imbalance is at the heart of many conditions which are marked …See details»
Medicxi portfolio company MiroBio to be acquired by Gilead …
Aug 4, 2022 · MiroBio is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune …See details»
Gilead Sciences signs agreement to acquire MiroBio for …
Aug 5, 2022 · Gilead Sciences has signed a definitive agreement for the acquisition of the complete outstanding share capital of MiroBio for $405m in cash.See details»
Gilead Sciences Completes Acquisition of MiroBio
Sep 20, 2022 · MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical …See details»
MiroBio Ltd. - Life-Sciences-Europe.com
Oct 8, 2018 · MiroBio was established as a spin-out from the University of Oxford in 2019. It is developing antibody modulators of immune cell receptors, an approach that has potential …See details»
Gilead Sciences to Acquire MiroBio - Business Wire
Aug 4, 2022 · MiroBio is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune …See details»
How a small UK biotech ended up in Gilead’s hands
Aug 5, 2022 · Gilead Sciences will acquire U.K.-based startup MiroBio, which is developing antibody drugs for autoimmune disorders, in a $405 million deal announced Thursday. MiroBio …See details»
Restoring Balance: MiroBio’s New CEO Shepherds Precision …
Sep 27, 2021 · MiroBio uses a proprietary discovery engine, I-ReSToRE, to comprehensively map the 70+ inhibitory checkpoint receptor pathways, in order to identify therapeutic opportunities …See details»
MiroBio Company Profile - Office Locations, Competitors ... - Craft
See insights on MiroBio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
MiroBio Continues Expansion of Executive Leadership Team with …
OXFORD, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- MiroBio, a biotechnology company advancing checkpoint agonist therapies to restore immune balance, today …See details»
Gilead Sciences Completes Acquisition of MiroBio
Sep 20, 2022 · MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical …See details»
Chasing Lilly, MiroBio raises $97M for autoimmune checkpoint R&D
Jun 29, 2022 · Medicxi, OrbiMed and other VCs have joined forces to help MiroBio flip immune checkpoint R&D on its head, committing $97 million to support development of BTLA and PD …See details»